Resmed Inc operates with a business model focused on the development and manufacturing of medical equipment for the management of sleep-disordered breathing and chronic respiratory diseases. The company's core products include devices for the treatment of sleep apnea, ventilators, and respiratory care solutions. Resmed Inc's business model emphasizes innovation and research to provide superior quality products to improve the lives of individuals suffering from these conditions. With a strong commitment to advancing respiratory healthcare, Resmed Inc has established itself as a leading global provider of sleep and respiratory medical devices and solutions.

Resmed Inc is primarily active in the industries of medical devices and sleep apnea solutions.

Resmed Inc faces competition from prominent companies in the market. Some of its main competitors include Philips Respironics, Fisher & Paykel Healthcare, and ResMed Ltd. These companies also specialize in providing solutions for sleep and respiratory disorders. Resmed Inc competes on various fronts in the market, including product innovation, quality, and customer service. Despite the competitive landscape, Resmed Inc has established itself as a leading player in the industry, offering cutting-edge products to improve sleep apnea and respiratory care.

ResMed Inc. is a leading global company that specializes in the development and manufacturing of innovative medical devices and solutions for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989, ResMed has evolved into a pioneer in sleep medicine, providing a wide range of products such as masks, devices, and software to improve respiratory health and enhance the quality of life for millions of patients worldwide. With a commitment to continuous innovation and cutting-edge technology, ResMed has established itself as a trusted and renowned name in the medical industry, dedicated to improving the well-being of individuals affected by respiratory disorders.

ResMed Inc has achieved significant milestones since its establishment. The company revolutionized the sleep apnea industry by introducing innovative and effective solutions for patients worldwide. ResMed pioneered the development of continuous positive airway pressure (CPAP) therapy, offering a breakthrough treatment method that significantly improved patient outcomes. Utilizing advanced technology and research, ResMed expanded its product line to include state-of-the-art sleep and respiratory care devices. The company's commitment to innovation and patient-centered solutions has led to numerous awards and recognitions, solidifying ResMed's position as a global leader in the sleep health industry. ResMed Inc continues to drive advancements in sleep apnea and respiratory care, improving the lives of millions.

Resmed Inc is primarily present in various countries and regions across the globe. The company has a strong presence in the United States, where its headquarters is located. It also operates and serves customers in Australia, Canada, France, Germany, Japan, and the United Kingdom. Additionally, Resmed Inc has expanded its reach to many other countries in Europe, Asia, and the Americas. With its global presence, Resmed Inc continues to provide innovative solutions and improve the well-being of individuals suffering from sleep apnea and other respiratory disorders.

Resmed Inc is a leading global medical technology company specializing in the development and manufacturing of innovative devices and solutions for sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company is dedicated to improving patients' quality of life by providing high-quality, patient-centric products and services. Resmed Inc's corporate philosophy centers around a commitment to innovation, excellence, and collaboration. By continuously investing in research and development, Resmed Inc aims to stay at the forefront of medical advancements and deliver effective and reliable solutions to the patients it serves.

Analysts currently set an average price target of 303.51 USD for the Resmed stock (median: 306.00 USD), implying +58.2 % versus the latest price. The consensus is based on 25 analyst ratings.

Resmed Analyst Price Targets 2026

25 analysts currently rate the Resmed stock: 16 recommend buying, 8 holding and 1 selling. For 2026, analysts expect Resmed to generate revenue of 5.65 B USD and earnings per share of 11.14 USD.

Resmed Analyst Price Targets 2026

Converted at the current exchange rate, the Resmed share trades at 168.48 EUR (191.89 USD).

The Resmed share (RMD) is listed on 10 stock exchanges, including: NYSE (RMD), Frankfurt (RME.F), München (RME.MU), Stuttgart (RME.SG), Düsseldorf (RME.DU), Berlin (RME.BE), London (0KW4.L), London (0KW4.L).

ResMed Inc. is a global company specialized in the development, manufacturing, and marketing of sleep apnea therapy products. Its business model is based on helping people around the world improve their sleep quality and promote their health. The company is divided into three main divisions: sleep and ventilation therapy, diagnostics, and software and services. The sleep and ventilation therapy division includes the production of ventilation devices, masks, and accessories that help keep the airway open during sleep and ensure optimal oxygen supply to the body. The diagnostics division offers solutions for detecting sleep disorders such as sleep apnea, including recording devices and software that can measure and analyze the patient's sleep behavior. The software and services division includes various solutions for medical professionals and patients to monitor and optimize therapy. ResMed Inc. is a pioneer in the industry and is considered an innovation leader in sleep apnea therapy. The company works closely with leading doctors and researchers to continuously develop new and improved products. ResMed Inc. also has a strong presence in the global market and operates in over 100 countries worldwide. One of ResMed Inc.'s most well-known products is the AirSense™ 10 AutoSet™, an intelligent ventilation device that automatically provides the patient with optimal respiratory support based on sensors and algorithms. The AirFit™ mask range from ResMed provides the patient with a comfortable and secure fit for successful therapy. ResMed Inc. also offers a variety of mobile apps that enable easy monitoring and management of the patient's therapy. ResMed Inc. also utilizes its industry-leading expertise to collaborate with other companies and organizations. For example, the company partners with medical device manufacturers and pharmaceutical companies to develop innovative solutions for the healthcare industry. ResMed Inc. has established itself as a trusted partner for medical professionals and patients. The company takes a holistic approach to sleep apnea therapy by engaging and educating patients and healthcare professionals. ResMed Inc. is always striving to improve the lives of patients with sleep apnea and provide them with a higher quality of life. Overall, ResMed Inc.'s business model is focused on the development and production of high-quality and innovative products for sleep apnea therapy. The company continually pursues new approaches to improve the quality of therapy for patients, always with the goal of promoting the health and well-being of its users.

The expected revenue of Resmed is 5.65 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Resmed is 1.64 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Resmed is currently 17.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Resmed stock.

The price-to-sales ratio (P/S) of Resmed is currently 4.99. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Resmed stock.

The Eulerpool Quality Score for Resmed is 8/10.

The ISIN of Resmed is US7611521078. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Resmed is 895878. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Resmed is RMD. The ticker symbol is used to trade Resmed shares on the stock exchange.

Over the past 12 months, Resmed paid a dividend of 2.26 USD . This corresponds to a dividend yield of about 1.18 %. For the coming 12 months, Resmed is expected to pay a dividend of 2.62 USD.

The current dividend yield of Resmed is 1.18 %.

Resmed pays a dividend, distributed in the months of , , , .

Resmed paid dividends every year for the past 14 years.

For the upcoming 12 months, dividends amounting to 2.62 USD are expected. This corresponds to a dividend yield of 1.36 %.

Resmed is assigned to the 'Health' sector.

In the year 2025, Resmed distributed 1.92 USD as dividends.

The dividends of Resmed are distributed in USD.